12/13
08:13 am
imrx
Immuneering Co. (NASDAQ: IMRX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating.
High
Report
Immuneering Co. (NASDAQ: IMRX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating.
12/13
08:13 am
imrx
Immuneering Co. (NASDAQ: IMRX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating.
High
Report
Immuneering Co. (NASDAQ: IMRX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating.
12/12
08:15 pm
imrx
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
High
Report
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
12/12
08:15 pm
imrx
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
High
Report
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
11/20
06:20 pm
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.
Medium
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.
11/20
05:53 pm
imrx
Rating for IMRX
Medium
Report
Rating for IMRX
11/14
08:15 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Low
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
11/14
05:19 am
imrx
Rating for IMRX
High
Report
Rating for IMRX
11/14
05:19 am
imrx
Rating for IMRX
High
Report
Rating for IMRX